{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","spread":"0.2","upperLimit":"1.0","value":"0.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Evaluation of Tmax following a single dose of 240 µg/kg plerixafor administered after 4 days of G-CSF mobilization. Tmax was determined from direct observation of the data.","dispersionType":"Full Range","groups":[{"description":"Subgroup of 13 participants (5 NHL and 8 MM) for which a pharmacokinetic (PK) profile was analyzed. Participants were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, followed by plerixafor 240 µg/kg the evening of day 4.","id":"OG000","title":"PK Subgroup"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic analysis was performed on a subgroup of participants from both treatment arms (5 NHL and 8 MM).","reportingStatus":"POSTED","timeFrame":"Day 5 - 0 to 10 hours post-first plerixafor dose","title":"Single-dose Time to Maximum Concentration of Plerixafor (Tmax)","type":"SECONDARY","unitOfMeasure":"hours"}